Stressor: 642
Title
Saracatinib
Stressor Overview
AOPs Including This Stressor
AOP Name | Evidence |
---|---|
Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Moderate |
Chemical Table
Preferred name | DTXID | Casrn | jchem_inchi_key | indigo_inchi_key | User term |
---|---|---|---|---|---|
Saracatinib | DTXSID90191355 | 379231-04-6 | OUKYUETWWIPKQR-UHFFFAOYSA-N | OUKYUETWWIPKQR-UHFFFAOYSA-N | Saracatinib |
References
Musumeci, F., Schenone, S., Brullo, C., & Botta, M. (2012). An update on dual Src/Abl inhibitors. Future Medicinal Chemistry, 4(6), 799–822. https://doi.org/10.4155/fmc.12.29
Hennequin, L. F., Allen, J., Breed, J., Curwen, J., Fennell, M., Green, T. P., Lambert-Van Der Brempt, C., Morgentin, R., Norman, R. A., Olivier, A., Otterbein, L., Plé, P. A., Warin, N., & Costello, G. (2006). N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy] -5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. Journal of Medicinal Chemistry, 49(22), 6465–6488. https://doi.org/10.1021/jm060434q
Green, T. P., Fennell, M., Whittaker, R., Curwen, J., Jacobs, V., Allen, J., Logie, A., Hargreaves, J., Hickinson, D. M., Wilkinson, R. W., Elvin, P., Boyer, B., Carragher, N., Plé, P. A., Bermingham, A., Holdgate, G. A., Ward, W. H. J., Hennequin, L. F., Davies, B. R., & Costello, G. F. (2009). Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology, 3(3), 248–261. https://doi.org/10.1016/j.molonc.2009.01.002
Kaufman, A. C., Salazar, S. V, Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., Van Dyck, C. H., Nygaard, H. B., Strittmatter, S. M., & Author, A. N. (2015). Fyn Inhibition Rescues Established Memory and Synapse Loss in Alzheimer Mice HHS Public Access Author manuscript. Ann Neurol, 77(6), 953–971. https://doi.org/10.1002/ana.24394